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ABSTRACT 
 
Pseudomonas aeruginosa (Pa) is a gram-negative opportunistic pathogen associated 
with life-threatening hospital-acquired and community-acquired infections affecting 
urinary tract, skin, eye, ear, and lungs. Antipseudomonal antibiotics are the most potent 
arsenals to treat Pa infections.  However, Pa infections are still common and stubborn 
bacterial infections due to elevated resistance levels against most of the antibiotics used 
in clinics. Treating Pa infections becomes even harder especially if antibiotic resistant 
Pa strains form biofilms and cystic structures in human body. In such cases, drug doses 
for treating bacterial infections can be up to one thousand fold higher than the necessary 
dose for treating infections caused by planktonic bacteria. Thus, there is an obvious 
need for novel therapies for fighting against Pa infections and Pa biofilms.  Recently, 
several studies performed on pyocins, proteinaceous bacterial toxins produced by Pa, to 
explore the potential of pyocins as novel antibiotics to treat Pa infections. Similar to 
other members of the bacteriocin family, pyocins mostly kill strains of the related 
species. There are three types of pyocins: S, R, and F pyocins. S-type pyocins are high 
molecular weight proteins and RF-type pyocins resemble bacteriophage tails. In this 
study, we applied four S-pyocins (S1, S2, S3, AP41) on Pa biofilms separately and in 
combination with six commonly used antibiotics (Tobramycin, Gentamicin, Colistin, 
Piperacillin, Ceftazidime, Ciprofloxacin) to determine the efficacy of S-pyocins in 
eradicating Pa biofilms and interactions between S-pyocins and antibiotics. We created 
Pa biofilms using Calgary Biofilm Device (CBD) to determine minimum biofilm 
eradication concentration (MBEC) of each antibiotics and S-pyocins separately and in 
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combination. This study aims to explore the potential use of S-pyocins as alternative 
drugs for eradicating biofilms where Pa biofilms show high resistance to 
antibiotics. Our preliminary results suggest wild type pyocins have a slight effect on Pa 
biofilms but there is an antagonism between pyocin AP41 and drugs Ciprofloxacin, and 
Colistin which can be used for selecting against drug resistant Pa strains. 	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ÖZET	  
	  
Pseudomonas aeruginosa (Pa) gram-negatif, oportünistik bir patojen olup genellikle 
hastanelerden bulaşarak ölümcül idrar yolları, deri, göz, kulak ve akciğer 
enfeksiyonlarına sebep olur. Antipseudomonal antibiyotikler günümüzde tedavi için 
kullanılan en yüksek potansiyelli tedavilerdir. Buna rağmen, Pa enfeksiyonları halen en 
çok görülen ve en inatçı enfeksiyonlardır. Bunun en temel sebebi ise Pa türlerinin 
antibiyotiklere karşı geliştirdiği yüksek direnç seviyeleridir. Hatta Pa biyofilm 
oluşturması durumunda antibiyotik direnci daha da artmakta ve tedavi daha da 
zorlaşmaktadır. Biyofilmler yapısal olarak antibiyotiklere planktonic fenotipe kıyasla 
bin kata kadar dirençli olabilmektedir. Dolayısıyla, yeni antibiyotik ajanlara ihtiyaç 
oldukça açıktır. Son yıllarda yapılan araştırmalarda pyosinlerin yani Pa tarafından 
üretilen toksik proteinlerin Pa tedavisinde kullanılmak üzere bir potansiyeli olduğu 
görülmüştür. Pyosinlerin özelliği sadece dar bir tür aralığını hedeflemesi ve sadece 
yakın türdeki Pa bakterilerini hedeflemesidir. Üç tip pyosin grubu vardır: S, R ve F 
pyosinler. S-pyosinler çözünebilen ve yüksek moleküler ağırlıkta proteinler olup, R ve 
F pyosinler bakteriyofaj şeklindedirler.  Bu çalışmada, dört adet S-pyosinin (S1, S2, S3 
ve AP41) Pa biyofilmleri üzerinde ayrı ayrı ve en çok kullanılan altı antibiyotik 
(Tobramisin, Gentamisin, Kolisin, Piperasillin, Ceftazidim ve Ciprofloxacin) ile 
antibiyotik çiftleri şeklinde denedik. Biyofilmleri Calgary Biyofilm Aleti kullanarak 
oluşturduk ve biyofilmlerin Minimum Biyofilm Eradikasyon Konsantrasyonlarını 
belirledik. Bu projenin hedefi Pa türleri üzerinde S-pyosinlerin ve antibiyotik-pyosin 
çiftlerinin Pa enfeksiyonları tedavisinde kullanılabilmesidir. İlk deney sonuçlar 
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gösteriyor ki pyosinlerin biyofilmler üzerindeki etkisi düşük olmakla birlikte AP41 
pyosin ve Ciprofloxacin ve Kolistin çiftleri antagonizme sebep olmakta. Bu 
antagonistik çiftler potansiyel olarak dirençli türlerin yok edilmesinde kullanılabilirler.  
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INTRODUCTION 	  
Identification of Pseudomonas aeruginosa 	  
Pseudomonas aeruginosa (Pa) is a gram-negative, versatile bacteria that can be found 
in diverse environments ranging from soil to medical devises and human-polluted 
environments such as sinks, swimming pools and sewers, and prostheses [1, 2, 3]. 
Since Pa is able to metabolize wide-range of nutrients, it is very ubiquitous in nature 
and human-polluted environments with organic materials such as sinks, swimming 
pools, and sewers [4]. 
 
It is an opportunistic bacterium that can infect nematodes, plants, and animals [5, 6, 
7]. In humans, Pa causes life-threatening hospital-acquired and community-acquired 
infections including sepsis, pneumonia, inflammation, gastrointestinal (GI) tract 
infections and skin infections, mostly affecting patients with cystic fibrosis and 
immunocompromised individuals such as cancer and AIDS patients, and burn 
victims[8]. 
 
Pathogenesis of Pa 
 
First, Pa enters into the body through breathing; open wounds or skin abrasions and 
then exerts its pathogenesis after binding to the related tissue. Pa multiplies until 
reaching to a critical biomass before virulence factors show their effect. Pa virulence 
factors mostly include exotoxins and endotoxins. An example for Pa virulence factors 
is the secretion of ExoS and ExoT with Type III secretion system leading eukaryotic 
host cell cytoskeleton disruption and cell death [9]. Another example is Exotoxin A, 
aka Pseudomonas Exotoxin, which inhibits elongation factor-2 leading to inhibition of 
protein synthesis and eventually death of eukaryotic cells [10]. 
 
Pa is a great threat for Cystic Fibrosis (CF) patients. 80% of adult CF patients have 
chronic Pa infection in their lungs [11]. Pa infects CF patients through airway and 
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once it is in, it moves to low oxygen environment. Normally aerobic Pa switches 
anaerobic mode and starts forming biofilms that will cause long-term, persistent 
infections, which are resistant to many antibiotic classes. 
 
Antibiotic Resistance of Pa 
 
Pa infections are very challenging to treat because of antibiotic resistance 
mechanisms. Especially in clinical isolates, antibiotic resistance is much higher due to 
the intense usage of antimicrobial agents (Table 1). 
	  
Table 1: Antibiotic resistance score differences between CF and non-CF patients [12] 
Intrinsic Resistance Mechanisms 
 
Increasing antibiotic resistance is achieved in several ways. The first way is general 
antibiotic resistance mechanisms (intrinsic) that Pa posses that are: 
 
1) Efflux pumps 
2) Inactivation of drugs 
3) Target modifications 
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There are several sources of antibiotic resistance in Pa.  Intrinsic mechanisms are one 
of them and include efflux pumps, drug inactivation, and target modification.  Pa 
strains use efflux pumps located on membranes to pump the antibiotics outside of the 
cell. There are four types of efflux pumps found in Pa all targeting different class of 
antibiotics: mexAB-oprM, mexXY-oprM, mexCD-oprJand mexEF-oprN. MexAB-
oprM pumps out mainly beta-lactams and quinolones [13], mexXY-oprM is 
responsible for aminoglycosides [14], and mexEF-oprN pumps carbapenems and 
quinolones [15]. Drug inactivation is another mechanism, which Pa uses to target to 
modify and inactivate antimicrobial molecules. AmpC gene is widely studied beta-
lactamase targeting antipseudomonal penicillins [16]. Pa can also modify targets of 
antimicrobial agents in order to prevent binding antibiotic molecules to related sites. 
16S rRNA modifications by methylation with 16S rRNA methylases such as RmtA 
and RmtD are shown to increase resistance against aminoglycoside group of 
antibiotics [17, 18]. 
 
Antibiotic Resistance of Biofilms 
 
Pa`s ability to form biofilms is another cause of elevated antibiotic resistance. 
Biofilms are structures formed by bacterial aggregates attached on a surface and 
surround themselves with an extracellular polymeric substances (EPS), composed of 
polysaccharides, proteins, DNA, lipids, and other substances [19]. 
 
Biofilm formation starts with attachment of motile bacteria to an appropriate surface. 
Surface attachment is usually achieved by non-specific hydrophobic bonding if a 
surface is nonliving. If the surface to be attached is a living environment, several 
molecular mechanisms play role in adherence leading to a specific binding. Short 
after initial attachment, bacteria start to form irreversible attachments with surface 
and the other bacteria. These attachments induce the expression of genes that produce 
EPS and glue the cells together forming a mature biofilm (Figure 1). 
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Figure 1: 4 steps of biofilm formation (1) Reversible attachment (2) Irreversible 
attachment (3) Maturation (4) Dispersion (Planktonization) [20] 
 
After biofilm is formed, bacteria of biofilm community can communicate via system 
called quorum sensing. Using pheromones, Pa communicates with other members to 
achieve cell aggregation, virulence, and polysaccharide formation via signal 
molecules detected by other bacterial cells and activating target gene expression [21, 
22]. 
 
Biofilms are much more difficult to eradicate than free-floating bacteria. Compared to 
minimum inhibitory concentration (MIC), which is the minimum concentration of 
antibiotic agent needed to inhibit bacterial growth of planktonic bacteria, 
concentration needed to eradicate biofilms is hundreds and in some cases even 
thousand times more than MIC [23] (Table 2). 
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Table 2: Comparison of MIC (Minimum Inhibitory Concentration and MBEC 
(Minimum Biofilm Eradication Concentration) values of Pseudomonas Aeruginosa 
ATCC 27853 [24] 
 
Resistance mechanisms of biofilms differ from planktonic cells. Antibiotic resistance 
mechanisms usually seen in bacteria such as efflux pumps, inactivation of drugs and 
target modifications are not the reason of high resistance to antibiotics. When biofilms 
are disrupted and the cells of biofilm are suspended in a medium, antibiotic resistance 
of biofilms dramatically decrease and MIC values become same with free-floating 
bacteria [25]. 
 
There are several hypotheses on the high antibiotic resistance of biofilms to 
antibiotics. One hypothesis is incomplete penetrance of antibiotic agents into the 
biofilm [26]. Antibiotics may be degraded easier when penetrance is slower. Another 
hypothesis is the modified chemical environment in biofilm structure. Antibiotics may 
be degraded or disrupted in different environments such as low or high pH values, 
changes in oxygen concentrations etc. [27]. One another hypothesis suggests that 
increased antibiotic resistance may be caused by cell differentiation after forming 
biofilms [28]. It is also suggested that positioning of bacteria throughout the slime can 
create heterogeneity that is some bacteria are able to access nutrient easier while some 
are not. Therefore, different metabolic activity will lead to different levels of 
susceptibility of members of biofilm community [29]. 
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Treatment of Pa infections is mostly achieved by antibiotic therapies. However, the 
more we use the antibiotics, the more antibiotic resistance is emerging. In addition, 
the number of novel antibiotics introduced by pharmaceutical companies is declining. 
It is obvious that novel therapies for antibiotic resistance bacteria are needed [30] 
(Figure 2). 
 
	  
Figure 2: Number of antibiotics approved by FDA as 4-year periods starting from 
1983 [31] 
 
	  	  	  
Bacteriocins 
 
Bacteriocins, discovered by A. Gratia in 1925, are small toxic proteins produced by 
wide variety of Bacteria and Archaea to inhibit or inhibit the growth of the closely 
related species [32]. In other words, bacteriocins are narrow spectrum antibiotics 
produced by bacteria to gain advantage on other bacteria. The first bacteriocin 
discovered killed E. coli therefore it is called “colicin”. 
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Colicins 
 
Colicins are produced by E. Coli and all colicin-producing genes are carried by 
plasmids. These plasmids are called pCol plasmid and colicin-producing bacteria are 
called colicinogenic bacteria. There are two main groups of colicin; group A and 
group B colicins that are classified according to the membrane proteins which 
translocate these toxins into target cell cytoplasm [33, 34]. Group A colicins are small 
proteins that are secreted to medium, while group B colicins are bigger and do not 
secreted to medium. Both groups of colicins show nuclease and pore-forming 
activities. 
 
As it has shown on the figure below, colicin operon has two genes: the first gene 
(toxin gene) codes for nuclease or pore-forming protein. Toxin gene is followed by 
the second gene (immunity gene) which codes for immunity protein. Immunity 
protein prevents colicin protein to attack and kill bacteriocin producing bacteria [35]. 
 
	  
Figure 3: Organization of colicin operons. PSOS: SOS promoters, Pim: Immunity 
Protein, T: Transcription Terminator, cxa: Colicin Killer Gene, cxi: Colicin Immunity 
Gene, cxl: Lysis Protein Gene [35] 
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Pyocins 
 
Pa is also known to produce bacteriocins called pyocins. 90% of Pa strains are known 
to produce pyocins. There are three types of pyocins classified according to their 
mechanisms of action and biological properties: F type, R type, and S type pyocins. F 
type (Flexuous) pyocins are group of pyocins have a structure and mechanism of 
action like contractile bacteriophages, such as bacteriophage λ.	  R	   type	  pyocins	   are	  also	   phage-­‐like	   proteins,	   yet	   their	   structure	   is	   similar	   to	   bacteriophage	   T4	  (Figure	  4).	  The	  main	  difference	  between	  R	  and	  F	  type	  pyocins	  is	  R	  type	  pyocins	  are	  contractile	  while	  F	  type	  pyocins	  are	  non-­‐contractile	  [36].	  
 
	  
Figure 4: Schematic representation of R and F type pyocins (CS = Contracted Sheath, 
BP = Base Plate, TFi = Tail Fibers, C = Core, DP = Distal Part, Fi = Fiber Part) [36] 
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S-type pyocins (S1, S2, S3, and AP41) are small nucleases that cause target cell DNA 
breakdown. Similar to colicins, pyocins protein consist of two components; the large 
component which is located to C-terminal of protein that exerts its nuclease activity, 
and the small component that do not show nuclease activity by itself and acts as an 
immunity protein [37] (Figure 5). 
 
	  
Figure 5: Genetic organization of pyocins. ORF1: Killing Protein, ORF2: Immunity 
Protein. [36] 
 
There is also a remarkable similarity between E2 group of colicins and the killing 
domains of S1, S2, S3 and AP41 pyocins. S1, S2, and AP41 nuclease domains show 
41% homology with E2 nuclease domain and 53% of their amino acids of immunity 
proteins are identical [38]. This situation also suggests that there is an evolutionary 
relationship between colicins and pyocins. They are possibly originated from a 
common ancestor. 
 
It is shown that S1, S2, S3, and AP41 are able to effectively kill sensitive strains of Pa 
and pyocins S2 is shown to be able to eradicate Pa biofilms [39]. It is obvious that 
pyocins are potent antibiotics to be used on Pa biofilms. 
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MATERIALS & METHODS 
 
Cloning 
 
In order to clone S1, S2, S3, and AP41 genes, plasmids from original sources (E. Coli 
cells) are extracted using QIAprep Spin Miniprep Kit (Table 3). Qiagen’s original 
protocol is used to extract plasmids (Appendix A). 
 
Strain Species Description 
pYMSS11 E. Coli (XL-1 Blue) 
Plasmid containing pyocin 
S1 gene in pUC119 
(Ampicillin Resistant) 
pYMPS1 E. Coli (XL-1 Blue) 
Plasmid containing pyocin 
S2 gene in pUC119 
(Ampicillin Resistant) 
pYS3.3 E. Coli (XL-1 Blue) 
Plasmid containing pyocin 
S3 gene in pUC8 
(Ampicillin Resistant) 
pYK211 E. Coli (XL-1 Blue) 
Plasmid containing pyocin 
AP41 gene in pUC8 
(Ampicillin Resistant) 	  
Table 3: Source strains for pyocins and vectors provided. 
 
Before extraction, E. coli cells possessing desired plasmids are cultured for 16 hours 
in 4ml of Luria Broth (LB) with 50ug/ml Ampicillin at a speed of 250rpm. After 
incubation, cells are centrifuged and pellet is lysed and lysate is loaded into the 
columns provided with the plasmid isolation kit. After plasmids are attached, column 
is washed with molecular biology grade water and desired plasmids are retained in 
30ul water and stored at -20 Celsius degree freezer. (See Appendix A for full 
protocol) 
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Concentrations of plasmids are measured using Nanodrop Spectrophotometer at 
OD600. Nanodrop spectrophotometer is an advantageous device that can measure 
concentrations using very small amounts 1.5ug or less. 
 
Extracted plasmids are confirmed by PCR reactions with Taq Polymerase. Primers are 
designed specifically for S1, S2, S3, and AP41 sequences in plasmids (Table 4). 
Primers are designed based on S-pyocin DNA sequences. The NCBI Genbank 
accession numbers of S-pyocin DNA sequences are D12707 for pyocin S1, D12708 
for pyocin S2, X77996 for pyocin S3, D12705 for pyocin AP41. PCR reactions are 
run in 1% agarose gel and ethidium bromide labeled PCR fragments are monitored 
under UV light. 
 
Genes Primer Name Primer Sequence 
S1 
S1 Forward 5' - ATGGCACGACCCATTGCT - 3' 
S1 Reverse 5' - TCACTT CCCTCCCTTGTG - 3' 
S2 
S2 Forward 5' - ATGGCTGTCAATGATTACGAA - 3' 
S2 Reverse 5' - TCACTTCCCTCCCTTGTG  - 3' 
S3 
S3 Forward 5' - ATGGCTGATGCACCAC - 3 
S3 Reverse 5' - TCAGTACCACCCCTGTTC - 3' 
AP41 
AP41 Forward 5' - ATGAGCGACGTTTTTGAC - 3' 
AP41 Reverse 5' - TTATTTCTCCTTACGTTTAAGT - 3' 
Table 4: Primers designed to verify and amplify pyocins S1, S2, S3, and AP41. 
 
Another set of primers is designed for sequence needed to use for cloning using 
Novagen Xa/LIC Cloning Kit. LIC stands for “Ligase Independent Cloning” and as 
the name suggests using this kit, target gene can be inserted into the vector provided 
without restriction enzymes or ligation. New primers had the very same sequence as 
showed in Table 4 plus the sequence 5’ - GGTATTGAGGGTCGC - 3’ is added to 5’ 
side of forward primer and sequence 5’ – AGAGGAGAGTTAGAGCC- 3’ is added 
to 5’ side of a reverse primer to create overhangs that matches with Xa/LIC vector. 
 
Plasmids acquired from E. coli are used as a template to generate desired overhangs 
using PCR. In this reaction Novagen KOD Hi-Fi DNA Polymerase is used instead of 
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Taq Polymerase because of its higher efficiency and lower mutation rate. Protocol 
provided by Novagen is used with temperatures provided by primer producing 
company (IDT). Primer annealing temperatures are later optimized for better results 
(Table 5). 
 
Genes TM Denaturation Extension 
S1 57C / 5s 98C / 15s 72C / 40s 
S2 57C / 5s 98C / 15s 72C / 40s 
S3 57C / 5s 98C / 15s 72C / 40s 
AP41 55C / 5s 98C / 15s 72C / 40s 
Table 5: Melting, denaturation and extension temperatures and times for PCR of 
pyocins S1, S2, S3, and AP41 
 
This method uses 3’ to 5’ endonuclease activity of T4 DNA Polymerase to create 
specific 12- or 15- base single stranded overhangs. Previously mentioned primers are 
designed to create overhangs that can match with overhangs of target vector. Vector 
and target DNA is complementary to each other and annealing is easily achieved 
(Figure 6). 
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Figure 6: Xa/LIC strategy diagram. Target gene is treated with T4 DNA Polymerase 
to create overhangs that matches with vector overhangs. Anneal is achieved in 
transformant cell after transformation. 
 
To prepare target DNA, double-stranded PCR product is treated with T4 DNA 
Polymerase and overhangs are created. Later enzyme is inactivated at 75 0C and later 
incubated with Xa/LIC vector for anneal. (See Appendix A for detailed protocol). 
 
After anneal reaction is complete, transformation to NovaBlue GigaSingles 
Competent Cells is performed using the standard protocol of Xa/LIC Cloning Kit (See 
appendix). Transformation was unsuccessful despite several trials possibly because of 
handling during shipping. Therefore, using NovaBlue GigaSingles Competent Cells 
that do not retain competency, new competent cells are prepared using Calcium 
Chloride and stored in Calcium Chloride and Glycerol solution at -800C freezer. 
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Newly prepared were used successfully afterwards and transformation is performed. 
Transformation results are controlled by culturing transformation reaction on LB agar 
plates with 30ug/ml Kanamycin in order to select successful transformants since 
Xa/LIC vector has Kanamycin resistance marker and therefore successful 
transformants possessed resistance against Kanamycin. NovaBlue cells are also 
checked on LB-agar plus Kanamycin plates as a negative control. Test plasmid 
provided by kit in order to test the efficiency of transformation efficiency is also used 
as a positive control. 
 
Successful transformants are then grown overnight in 4ml LB broth with 30ug/ml 
Kanamycin and plasmid extraction is performed, again using QIAprep Spin Miniprep 
Kit. Using Nanodrop concentration is performed and plasmids are checked if desired 
gene transformed is present via PCR. Taq Polymerase kit and primers designed for 
control is used. PCR-positive plasmids are stored at -200C. 
 
Plasmids are later transformed into E. coli BL21 DE3 expression cells. These cells are 
able to express T7 RNA Polymerase that can induce expression of desired gene on 
Xa/LIC vector that has T7 promoter upstream of target gene (Figure 7) .  Plus, E. coli 
BL21(DE3) pLysS cells are also used for transformation. However, both expression 
cells were unable to be transformed like NovaBlue cells. Therefore, using these cells, 
new competent cells are prepared using previously mentioned competent cell 
protocol. Transformation reaction is tested on LB agar plates with 30ug/ml 
Kanamycin and successful transformants are grown overnight in LB broth with 
30ug/ml Kanamycin and stored at -800C freezer in 15% glycerol solution for further 
use. 
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Figure 7: Control of expression of pET vector in BL21(DE3) cells. 
 
Expression 
 
Successful transformants selected are tested against sensitive strains Pa NIH3, Pa 
PML1516d, and Pa 7NSK2. Pa NIH3 and Pa PML1516d are known to be sensitive 
against pyocins S1, S2, and AP41 while Pa 7NSK2 is known to show sensitivity only 
to pyocin S3. 
 
The test is called “Killing Assay”. In Killing Assay, sensitive strains are equally 
distributed to a LB-agar plate including IPTG (1mM) and pyocin-producing strains 
are spotted on sensitive strain usually ranging from 2ul to 10ul. Spotted plates are left 
overnight in 370C incubator and killing zones, the area near the spotted producer 
bacteria where there is no bacterial growth, are observed. There are also negative 
controls (sensitive and non-producing strains) included. 
 
Bacteria that are able to kill sensitive bacteria by creating a killing zone are grown 
overnight in 10 ml LB with an antibiotic to preserve plasmid until it reaches to 
OD600 ~3.00. Afterwards, they are transferred to a 1 L LB with the same amount of 
antibiotic and let grow in 370C shaker until it reaches OD600 ~0.5-0.6. When desired 
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OD600 is reached, expression of S-pyocins is induced with IPTG (1mM) After 
induction, bacteria are grown until it reaches OD600 1.2. 
 
After reaching desired OD, bacteria are transferred to 0.5L Sorvall centrifuge bottles 
on the ice. Using Sorvall centrifuge and SLA-3000 rotor, bacteria are centrifuged for 
30 minutes at 7,000rpm. Pellet, including bacteria and pyocins, is transferred to 
plastic beakers and weighed. After centrifugation pellets are always worked on ice. 
Pellets are stored in -800C until the next step. 
 
The next step after first centrifugation is lysis where pellet is lysed and all bacterial 
proteins are spread in solution. Lysis is done using both chemicals and physical 
disruption. First, pellet is resuspended in 20ml Buffer A, which is used in purification 
step. Buffer A is composed of 50mM Tris, 200mM NaCl, and pH of Buffer A is set to 
8.00. After resuspension, 1 Complete Tablet without EDTA (protease inhibitor), 
0.5mM PMSF (protease inhibitor), and 1mg/ml Lysozyme (Fluka Chicken Egg 
White) is added to solution and in cold room, where temperature is 4C, solution is 
stirred with a magnetic stirrer for 1 hour. 
 
Solution is sonicated with a pulse 6 seconds on, 9 seconds of with amplitude of 36%. 
Sonication was performed for 30 minutes and held in cold room (+40C degree). 
 
As an alternative way for lysis, BugBuster Protein Extraction Reagent of Novagen is 
used. The difference between two methods were, in BugBuster method, pellet is 
resuspended in BugBuster solution at room temperature and Benzoase nuclease and r-
Lysozyme is added and solution is stirred at room temperature. No physical disruption 
is required. However, this method is abandoned because of low activity of lysate 
extracted using this method compared to previously explained method. 
 
Solution is then transferred to 50ml pre-cold centrifuge bottles and centrifuged at 
15,000rpm for 1 hour. Since S-type pyocins are known to be soluble, supernatant is 
fully saved and immediately taken to purification step. Pellet is resuspended in sterile 
water and 1ml pellet is saved for Killing Assay, and SDS-PAGE analyses. 
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Purification 
 
Purification is performed using AKTA FPLC (Fast Protein Liquid Chromatography) 
machine. AKTA FPLC machine is used for liquid chromatography to separate desired 
proteins from a pool of proteins using a proper column (Figure 8). Since S-pyocins 
were tagged with 6xHistidine-tag, 1ml and 5ml nickel-affinity columns from GE 
Healthcare were used. Since nickel has an affinity for 6xHistidine-tag, it is expected 
that proteins possessing desired tag would bind to column while others are passing 
through. 
 
	  
Figure 8: Diagram of AKTA-FPLC Machine retrieved from manual 
 
There are two buffers used for purification; Buffer A and Buffer B. Buffer A is very 
same buffer used for resuspension of bacterial pellet. Buffer B is Buffer A and 
imidazole (500mM) added. Buffer A is used to pass all protein solution through 
column to make desired protein to bind to column and Buffer B is later used to elute 
desired protein from affinity column. 
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First, supernatant from lysis reaction is loaded into 50ml loop. FPLC Machine (the 
path of solution including column) is washed with sterile water, and buffer A. After 
washing was complete, solution in loop is injected into the column. During passage 
from column, UV and conductivity is monitored and recorded. Flow-through is 
collected for further testing to be sure if desired protein is successfully bound to the 
column. After all solution is passed through the column and UV and conductivity 
values were stabilized, Buffer B (including imidazole) is added with an increasing 
concentration starting from 0-100% until UV values gave a peak. The peak usually 
means that there is another set of proteins passing the UV reader, therefore one of the 
peaks given theoretically include the desired protein. Fractions corresponding to 
peaks and other control points were collected and stored at +40C refrigerator for SDS-
PAGE analysis. 
 
Fractions collected are run in SDS-PAGE gel along with protein markers and pre-
purification samples (pellet after lysis, and flow-through). SDS-PAGE gel consisted 
of two parts: 12% Separating Gel, and 5% Stacking Gel (See Appendix for 
Ingredients). Before loading into SDS-PAGE gel, samples are boiled at 95C for 10 
minutes with a loading dye (beta-mercaptoethanol) in 1:1 concentration. 
 
SDS-PAGE gel is run for 45 minutes at 26mA and gel is later boiled twice and 
stained with Coomassie Brilliant Blue. Staining is performed 5 minutes and later gel 
is boiled with water in microwave several times before letting gel overnight for 
destaining. After overnight destaining, samples are compared with protein marker and 
results are photographed. Fractions with desired molecular weight are stored at +40C 
refrigerator. 
 
Biofilm Formation 
 
For biofilm formation, Calgary Biofilm Device (CBD) is used. CBD is a special assay 
for determining antibiotics susceptibilities of biofilms. Biofilms are formed on 96-
well plate lid containing 96 pegs after exposure to planktonic cell culture for a certain 
period of time. 
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Figure 9:Diagram of Calgary Biofilm Device framework. 
 
In order to start a new experiment, a LB-agar plate was streaked with biofilm-
producing bacteria and plate was incubated overnight at 370C incubator. A single 
colony is spread to a new LB-agar plate and incubation is again done in same 
conditions overnight. In the third day, bacteria is scraped with sterile toothpick and 
resuspended in LB. Resuspension is diluted to 1 MacFarland standard as stated in 
protocol provided by CBD kit (See Appendix for protocol). 1 MacFarland standard is 
OD600 0.257 in 600nm wavelength. 1ml of MacFarland standard of resuspension is 
diluted to 1:30 and 150ul is added to each well of CBD and lid having 96 pegs is 
closed. CBD is then incubated in a VWR Signature Incubating Rocking Platform 
Shaker at a 7-degree tilt angle, 10rpm speed, and 370C degree for 6 hours. After 
biofilms were formed, new 96-well plate with a desired antibiotic gradient is prepared 
and biofilms produced is exposed to antimicrobial agents in, what is called, challenge 
plate after pegs are washed with sterile physiological saline solution (0.9% NaCl, 
autoclaved) (Figure 9). 
 
Interaction Testing 
 
MBEC values of biofilms are determined using CBD. Biofilms on the pegs of 96-well 
plate are exposed to challenge plate with a gradient of antibiotics and later remaining 
biofilms are recovered on a fresh 96-well plate with LB without antibiotics. 
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Planktonic cell MIC values are also determined by creating a gradient of antibiotics. 
Later, gradient showing MIC values are duplicated and other antimicrobial agent 
(pyocins, or antibiotics) are added. Then two results are compared to see if there is a 
shift in MIC values. According to the result, it can be concluded that interaction is 
synergistic, antagonistic, or additive. 
RESULTS 
 
Cloning 
 
Vectors isolated from pyocin sources are run on 1% agarose gel and extraction is 
confirmed (Figure 10)	  
	  
Figure 10: Template vector confirmations from source E. Coli possessing S1, S2, S3, 
and AP41 genes in pUC plasmids. Vector DNA’s are extracted with Miniprep Kit of 
QIAGEN. 	  Later,	  template	  DNA	  is	  prepared	  using	  designed	  primers	  for	  creating	  overhangs.	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Figure 11: Template DNA amplification from vector DNA’s isolated from source. 
Expected lengths for PCR products were 1856bp, 2056bp, 2300bp, and 2333bp for 
S1, S2, S3, and AP41, respectively. Negative control didn’t include template DNA. C: 
Negative Control. 
 
PCR reaction for pyocin AP41 is repeated with a melting temperature of 570C since 
acquired DNA after first PCR was low for pyocin AP41 compared to others. (For S1, 
S2, and S3 suggested melting temperature was 550C). Results are shown in Figure 12. 
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Figure 12: Template DNA amplification for AP41 for melting temperature of 57C. 
Expected size is 2333bp for AP41.  -C: Negative Control. 
 
Later, confirmed target DNA is annealed with Xa/LIC vector and transformed into 
Nova GigaSingles cells after creating overhangs with T4 DNA Polymerase enzyme. 
Transformed colonies are picked and grown overnight to extract their plasmid and 
verify successful anneal. 
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Figure 13: AP41 + Xa/LIC plasmid confirmation for 15 samples. Xa/LIC vector is 
~5.6kb and expected size for final product is 8100bp. 
 
Later, vectors isolated are verified with PCR using primers specific to related pyocin 
gene. 
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A                                                                   B 
 
C             D 
 
E      F 
	  
Figure 14: Vector confirmation with PCR for S1, S2, S3, and AP41. A. Lanes 1-10 
PCR product of Xa/LIC+S1. B. Lanes 11-18 PCR product of Xa/LIC+S1 C. Lanes 
19-28 PCR product of Xa/LIC+AP41 D.  Lanes 29-38 PCR product of Xa/LIC+AP41 
E. Lanes 1-10 PCR product of Xa/LIC+S2 F. Lanes 1-10 PCR product of Xa/LIC+S3. 
+C: Positive Control, -C: Negative Control. 
 
Expression 
 
Using 1mM IPTG, cells containing recombinant plasmids are induced and tested 
against sensitive cells via Killing Assay. Later, successful killers (cells producing 
effective killing proteins) are collected and stored -800C. However, since killing was 
weak and thus it was not possible to take photographs. 
 
In the next steps, samples are induced in 1L cultures with an IPTG concentration of 
1mM. Later cells are centrifuged and lysed with BugBuster reagent. Lysates (Cell 
Free Extracts) are tested against sensitive bacteria via Killing Assay. Cell Free 
Extracts (CFE) of competent cells are also spotted on sensitive lawn as a negative 
control. 
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Figure 15: Cell Free Extract activity control. AP41 pellet and CFE are tested on the 
lawn of NIH3 sensitive cells. BL21(DE3) cells are tested as a negative control. 
 
Pyocins S1, S2, S3 samples did not show a strong killing activity as seen in pyocin 
AP41. Therefore, cloning steps are repeated and optimized further. However, despite 
having positive results for vectors possessing the desired gene, expression products 
were able to show a little or not activity. For pyocins S1 and S3 there were a little 
activity compared to pyocins AP41 and for pyocin S2 killing activity were not visible 
on sensitive lawn. 
 
In order to solve the problem, expression steps are optimized further. Three different 
temperatures (260C, 300C, 370C), and IPTG concentrations (0.4mM, 0.8mM, 1mM) 
are tested for pyocins S1, S3, and AP41 and results are scored. Novagen BugBuster 
solution  is used for lysis in this experiment. 
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Table 6: Temperatures, and IPTG concentrations for S1, S3, and AP41 samples. + is 
the smallest killing zone, +++ is the best killing zone observed. 
 
Later, expressions carried out with the information acquired from Table 6 however, 
activity of expression products were very low. However, samples showing the best 
activity compared to the others tested were stored and used in purification steps. 
 
Purification 
 
Purification result for S1: 
	  
Figure 16: UV peaks of purification using AKTA-FPLC for S1 There are two peaks at 
~10% buffer B concentration and ~20% buffer B concentration. Fractions underneath 
are collected and loaded into SDS gel to find out sizes. 
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Figure 17: SDS gel result for S1. Length shown with red arrow is expected size of S1 
protein ~66kDa. 
 
 
 
Purification result for S3: 
 
	  
Figure 18: UV peak of purification using AKTA-FPLC for S3 There is one peak at 
~20% buffer B concentration. Fractions underneath are collected and loaded into SDS 
gel to find out sizes. 
 
	   31	  
	  
Figure 19: SDS gel result for S3. Length shown with red arrow is expected size of S1 
protein ~85kDa. 
 
 
 
 
 
 
Purification result for AP41: 
	  
Figure 20: UV peak of purification using AKTA-FPLC for AP41 There is one peak at 
~20% buffer B concentration. Fractions underneath are collected and loaded into SDS 
gel to find out sizes. 
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Figure 21: SDS gel result for AP41. Length shown with red arrow is expected size of 
AP41 protein ~85kDa. 
 
 
Contrary to expectations that low activity of proteins can be caused by low 
concentrations of protein and purification may lead to a better killing activity on 
sensitive lawn, purified proteins didn’t show strong killing activity on sensitive Pa 
lawns. 
 
The reason is proposed to be the method of lysis and during lysis; proteins may be 
degraded or damaged. Therefore, lysis is repeated with lysozyme, PMSF, and 
complete tablets. 
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Figure 22: Repeated AP41 purification with a lysis method using lysozyme 
 
	  
Figure 23: SDS gel results for AP41 purified with a lysis method using lysozyme. M: 
Marker, SN: Supernatant, P: Pellet, FT: Flowthrough, 6, 20, and 23: Fractions. 
 
Expected size bands and low killing activity showed that there is a functioning protein 
even though it is not enough in concentration; therefore Anion Exchange 
Chromatography is performed on fractions number 17 to 30 in order to have more 
purified protein. 
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Figure 24: Anion exchange for AP41 for fractions collected from affinity 
chromatography. Several peaks are observed for theoretically different charged 
proteins. 
 
Fractions collected didn’t show any killing activity. In order to find out the reason 
there is no activity, Western Blot is applied for fractions under the peaks. 
 
	  
Figure 25: Western blot results for AP41 lysates 
 
Results showed that 6xHis tag is available in lysates suggesting proteins somehow 
lost the activity during protein purification. 
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Since it was not possible to purify His-tagged protein for further studies, Cell Free 
Extract (CFE) is used. Before using CFE, producer bacteria are spot on sensitive lawn 
and grown overnight. 
 
	  
Figure 26: Killing assay for S1 producer. 3ml overnight cultures are centrifuged and 
resuspended in 100ul LB and spotted on sensitive lawn (NIH3). Medium of overnight 
cultures are spotted as well. XL-1 Blue pellet and medium are spotted as negative 
control. 
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Figure 27: Killing assay for S2 producer. 3ml overnight cultures are centrifuged and 
resuspended in 100ul LB and spotted on sensitive lawn (NIH3). Medium of overnight 
cultures are spotted as well. XL-1 Blue pellet and medium are spotted as negative 
control. 
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Figure 28: Killing assay for S1 producer. 3ml overnight cultures are centrifuged and 
resuspended in 100ul LB and spotted on sensitive lawn (7NSK2). Medium of 
overnight cultures are spotted as well. XL-1 Blue pellet and medium are spotted as 
negative control. 
 
 
pYK211, producer of AP41, didn’t show a killing activity on sensitive strain, 
therefore it is cloned in BL21(DE3) cells from original plasmid from pYK211. New 
clones showed killing activity. 
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Figure 29: Transformants killing assay verification for AP41. Colonies are collected 
from transformation plate with sterile toothpicks and spotted on sensitive lawn of Pa 
NIH3. Best killers are cultured overnight and stored for later usage. NIH3 pellet is 
spotted as a negative control. 
 
After confirmation, all producers are grown in 1L LB culture and pellet is lysed with 
lysozyme and centrifuged. Supernatant after lysis, Cell Free Extract, is used for 
further experiments. 
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A                                                             B 
	  
Figure 30: A. AP41 CFE spotted on Pa NIH3 lawn. B. S1 CFE spotted on NIH3 lawn. 
Both plates are spotted with decreasing concentrations of CFE. 
 
 
	  
Figure 31: S3 CFE, medium, and pellet are tested on sensitive lawn of 7NSK2. XL-1 
Blue cells are used as a negative control. 
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Interactions 
 
Before testing CFE on biofilms it is aimed to determine Minimum Inhibitory 
Concentration (MIC) for planktonic cells and Minimum Biofilm Eradication 
Concentration (MBEC). Tobramycin, Gentamicin, Colistin, Piperacillin, Ceftazidime, 
and Ciprofloxacin are tested on biofilm cells as a gradient of concentrations. At the 
same time for further optimization of biofilm formation time, biofilms at different 
hours are tested. 
 
 
Figure 32: Number of cells in biofilms of NIH3 at 2, 4, and 6 hours respectively 
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Figure 33: Antibiotic response of NIH3 biofilms at different hours. Biofilms grown 2, 
4, 6, and 8 hours are exposed to decreasing gradient of antibiotics. Growths of each 
concentration are shown in Y-label as OD 595 measurements. Antibiotic 
concentrations are diluted by 50% in each dilution. Starting antibiotic concentrations 
were 10mg/ml, 50mg/ml, 50mg/ml, 50mg/ml, 50mg/ml, and 6mg/ml for Tobramycin, 
Gentamicin, Colistin, Piperacillin, Ceftazidime, and Ciprofloxacin, respectively. 
 
Colistin and Ciprofloxacin were chosen since these drugs in a soluble range achieved 
eradication of biofilms. Pa NIH3 biofilms are tested with Colistin and Ciprofloxacin 
in 4, 6, and 8 hours. 
 
	  
Figure 34: Growths of NIH3 biofilms in decreasing concentration gradient of Colistin 
and Ciprofloxacin. Concentrations are highest in X-axis value (1) and decreasing by 
10% until concentration 6. Y-axis represents growth measured by OD 595 of cell 
culture. Starting concentration for Colistin at 80ug/ml and for Ciprofloxacin 20ug/ml. 
OD<0.1 is considered as no growth. 
 
 
After killing ranges are detected, drugs are tested on Pa NIH3 planktonic cells with 
pyocin AP41. 
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Figure 35: Shift Assay for Ciprofloxacin and AP41. Ciprofloxacin concentration is 
decreased by 10% as a gradient starting from X-axis label (1) until (10). X-axis label 
(11) is used as a growth control without an antibiotic. For CIP+AP41, 10ul CFE of 
AP41 is added to each well of Ciprofloxacin gradient. CIP+BL21 is negative control 
where 10ul CFE extract of BL21(DE3) cells are added to each dilution of antibiotic 
gradient of Ciprofloxacin. Ciprofloxacin concentration is started from 0.8ug/ml 
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Figure 36: Shift Assay for Colistin and AP41. Colistin concentration is decreased by 
10% as a gradient starting from X-axis label (1) until (10). X-axis label (11) is used as 
a growth control without an antibiotic. For Colistin+AP41, 10ul CFE of AP41 is 
added to each well of Colistin gradient. 
DISCUSSION 
 
Anti-pseudomonal drugs Tobramycin, Gentamicin, Colistin, Piperacillin, 
Ceftazidime, and Ciprofloxacin have been used for the treatment of Pa infections  for 
a long time. However, increasing antibiotic resistance observed in Pa strains causes a 
significant need for investigating novel therapies such as drug-drug interactions, and 
other antimicrobial elements such as bacteriocins. 
 
Since we know that pyocins can be used for eradication Pa biofilms [39] we 
hypothesized pyocins and synergistic pyocin-drug interactions could be used for 
inhibition of free-floating Pa cells, and also eradication of Pa biofilms. Therefore, in 
this study, we tested narrow-spectrum killer proteins, S-pyocins, against antibiotics 
Ciprofloxacin and Colistin. 
 
In order to have pure pyocins, S-pyocin genes are cloned into Novagen pET-30 
Xa/LIC System and expression is induced by adding 1mM IPTG concentration. After 
extraction of the cells, amount of protein for performing killing assays or MIC/MBEC 
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tests was not enough, or activity of extracted proteins were too low to see a visible 
killing. Therefore, several optimization steps are performed. IPTG concentrations at 
0.4mM, 0.8mM, and 1mM were tried however there was no change in protein activity 
observed. Three temperatures (260C, 300C, and 370C) are tested along with IPTG 
concentrations for pyocins S1, S3, and AP41. However there is no significant change 
in killing activity observed. Possible optimization could be cloning with a system 
other than pET-30 Xa/LIC considering the reason of inactivity could’ve been cloning 
system, buffer and pH arrangements since the reason of inactivity could’ve been 
unfolding or degradation of pyocin in the buffers where extracts are stored. Using 
CFEs from E. coli cells which possess S-pyocin genes (Table 3) is more feasible for 
this study instead of further optimization of cloning and expression in pET30 Xa/LIC 
system. 
 
We tested killing activity of CFEs obtained from E. coli cells on S-pyocin sensitive Pa 
cells to eliminate the potential interaction between proteins of E. coli and S-pyocin 
sensitive Pa cells. Results of these tests showed that proteins of E. coli cells do not 
kill S-pyocin sensitive Pa NIH3 cells. 
 
Quantification of S-pyocin amount in CFE is one of the challenges. It is not possible 
to determine the S-pyocin amount as µg in the CFE obtained from E. coli cells with 
plasmids possessing S-pyocin genes. For this reason instead of testing different S-
pyocin concentration gradients with drug gradients, constant amount of CFE is used 
against antibiotic gradient. The aim was to make MIC value of antibiotic shift to both 
sides that would lead observing a synergy or antagonism (Shift Assay). If MIC value 
for bacteria is higher when S-pyocin and antibiotic were added together compared to 
only antibiotic condition, the interaction is considered as antagonistic since addition 
of the second molecule (in this case S- pyocin or CFE containing S-pyocin) prevent 
killing activity of antibiotic. If MIC is shifted the other way, i.e. it is decreased; there 
is a possible synergy between two molecules. 
 
Results of this study suggested a potential antagonistic interaction between pyocin 
AP41-Ciprofloxacin and pyocin AP41-Colistin drug combinations (Figures 35 and 
36). 
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We also tested antibiotics and S-pyocins on Pa NIH3 biofilms. However, only 
Ciprofloxacin, Colistin, and Gentamicin were able to show killing activity. S-pyocins 
were also not effective against Pa NIH3 biofilms formed. Nevertheless, S-pyocins 
may be more effective on biofilms if they are more pure and concentrated. 
 
 
 
FURTHER STUDIES 
 
For the next period, all possible drug-pyocin pairs will be tested using shift assay and 
possible synergies and antagonisms will be monitored. Same assay will also be 
applied to biofilms. 
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APPENDIX 
 
Protocol: Plasmid DNA Purification using the QIAprep Spin Miniprep Kit and a 
Microcentrifuge 
 
This protocol is designed for purification of up to 20 µg of high-copy plasmid DNA 
from 1–5 ml overnight cultures of E. coli in LB medium. For purification of low-copy 
plasmids and cosmids, large plasmids (>10 kb), and DNA prepared using other 
methods, refer to the recommendations on page 34. 
Please read “Important Notes” on pages 12–18 before starting. Note: All protocol 
steps should be carried out at room temperature (15–25°C). 
Procedure 
1. Resuspend pelleted bacterial cells in 250 µl Buffer P1 
and transfer to a micro- centrifuge tube.  Ensure that RNase A has been added 
to Buffer P1. No cell clumps should be visible after resuspension of the pellet. 
 If LyseBlue reagent has been added to Buffer P1, vigorously shake the buffer 
bottle to ensure LyseBlue particles are completely dissolved. The bacteria 
should be resuspended completely by vortexing or pipetting up and down until 
no cell clumps remain. 
2. Add 250 µl Buffer P2 and mix thoroughly by inverting 
the tube 4–6 times.  Mix gently by inverting the tube. Do not vortex, as this 
will result in shearing of genomic DNA. If necessary, continue inverting the 
tube until the solution becomes viscous and slightly clear. Do not allow the 
lysis reaction to proceed for more than 5 min.  If LyseBlue has been added to 
Buffer P1 the cell suspension will turn blue after addi- tion of Buffer P2. 
Mixing should result in a homogeneously colored suspension. If the 
suspension contains localized colorless regions or if brownish cell clumps are 
still visible, continue mixing the solution until a homogeneously colored 
suspension is achieved. 
3. Add 350 µl Buffer N3 and mix immediately and 
thoroughly by inverting the tube 4–6 times.  To avoid localized precipitation, 
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mix the solution thoroughly, immediately after addition of Buffer N3. Large 
culture volumes (e.g. ≥5 ml) may require inverting up to 10 times. The 
solution should become cloudy.  If LyseBlue reagent has been used, the 
suspension should be mixed until all trace of blue has gone and the suspension 
is colorless. A homogeneous colorless sus- pension indicates that the SDS has 
been effectively precipitated. 
4. Centrifuge for 10 min at 13,000 rpm (~17,900 x g) in a 
table-top microcentrifuge. A compact white pellet will form. 
5. Apply the supernatants from step 4 to the QIAprep spin 
column by decanting or pipetting. 
6. Centrifuge for 30–60 s. Discard the flow-through. 
7. Recommended: Wash the QIAprep spin column by 
adding 0.5 ml Buffer PB and centrifuging for 30–60 s. Discard the flow-
through.  This step is necessary to remove trace nuclease activity when using 
endA+ strains such as the JM series, HB101 and its derivatives, or any wild-
type strain, which have high levels of nuclease activity or high carbohydrate 
content. Host strains such as XL-1 Blue and DH5®α do not require this 
additional wash step. 
8. Wash QIAprep spin column by adding 0.75 ml Buffer 
PE and centrifuging for 30–60 s. 
9. Discard the flow-through, and centrifuge at full speed for 
an additional 1 min to remove residual wash buffer.  Important: Residual 
wash buffer will not be completely removed unless the flow-through is 
discarded before this additional centrifugation. Residual ethanol from Buffer 
PE may inhibit subsequent enzymatic reactions. 
10. Place the QIAprep column in a clean 1.5 ml 
microcentrifuge tube. To elute DNA, add 50 µl Buffer EB (10 mM Tris·Cl, 
pH 8.5) or water to the center of each QIAprep spin column, let stand for 1 
min, and centrifuge for 1 min. 
 
Protocol: Annealing Reaction for Xa/LIC Cloning Kits 
 
	   52	  
1. For each insert, assemble the following components in a sterile 1.5-ml micro 
centrifuge tube 
 
• 1 µl Xa/LIC Vector 
• 2 µl T4 DNA Polymerase treated Xa/LIC insert (0.02 
pmol) 
Incubate at 22°C for 5 min, then add: 
• 1 µl 25 mM EDTA 
• 4 µl Total volume 
 
2. Mix by stirring with the pipet tip and incubate at 22°C for 5 min. 
 
Notes: 
 
a) Greater volumes of the treated insert may be used; however, the concentration of 
vector in the reaction will decrease and subsequently fewer nanograms will be plated 
if a constant amount of annealing reaction is used for transformation. 
 
b) Annealing is complete within 5 min of incubation; reactions can be incubated up to 
1 h with equivalent results. 	  
